通过新型认知增强剂d-戈瓦丁增强前额叶皮层的多巴胺功能
Maya O Nesbit1, Soyon Ahn1, Haiyan Zou1
1Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
Neuropharmacology
|January 20, 2024
概括
d-戈瓦丁通过增加中部前额叶皮质 (mPFC) 中的多巴胺来增强工作记忆. 这种效果是由mPFC和VTA之间的依赖谷氨酸的反循环调节的,提供了一种新的益智药物策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 认知障碍是精神疾病如精神分裂症的一个重大挑战.
- 目前对认知缺陷的治疗方法有限.
- d-戈瓦丁 (d-GOV) 在增强依赖于前额叶皮层 (PFC) 的认知功能方面表现有前途.
研究的目的:
- 阐明d-GOV在中间PFC (mPFC) 中对多巴胺 (DA) 流动的优先强化背后的特定机制.
- 调查谷氨酸转移在d-GOV的认知效应中的作用.
主要方法:
- 在雄性大鼠体内进行脑透析,以测量mPFC中的DA和北上腺素 (NE) 流量.
- 将d-GOV注射到mPFC或腹膜区域 (VTA).
- 在mPFC或VTA中,药理学阻断了谷氨基基的传播.
主要成果:
- 与NE相比,系统性或mPFC内部的d-GOV给药选择性地增加了mPFC中的DA流量.
- 在mPFC或VTA中通过阻断谷氨基基质的传输来消除d-GOV对mPFC的DA流量的影响.
- d-GOV优选增强的mPFC DA,而不会影响核心 accumbens DA释放.
结论:
- d-GOV选择性地准了mPFC多巴胺系统.
- d-GOV的前认知效应取决于一个完好无损的质干细胞通路,涉及mPFC和VTA.
- d-GOV可能通过启动PFC-VTA反循环来起作用,这代表了一种用于精神疾病认知增强的新型治疗策略.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126
01:25Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
01:25Long-term Potentiation
2.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.8K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:24Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
197
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
197